Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Testing effectiveness (Phase 2)Study completedNCT01022996
What this trial is testing

Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.

Who this might be right for
Hodgkin Lymphoma
Novartis Pharmaceuticals 57
Testing effectiveness (Phase 2)UnknownNCT03077828
What this trial is testing

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Lymphocyte-Rich Classical Hodgkin LymphomaRecurrent Lymphocyte-Depleted Classical Hodgkin LymphomaRecurrent Mixed Cellularity Classical Hodgkin Lymphoma+4 more
Northwestern University 43
Testing effectiveness (Phase 2)Study completedNCT00070304
What this trial is testing

Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Children's Oncology Group 33
Testing effectiveness (Phase 2)Study completedNCT00381940
What this trial is testing

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+17 more
National Cancer Institute (NCI) 26
Early research (Phase 1)Study completedNCT02168140
What this trial is testing

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+14 more
Wake Forest University Health Sciences 16
Early research (Phase 1)UnknownNCT03374007
What this trial is testing

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

Who this might be right for
Advanced Solid TumorRecurrent Solid TumorLymphoma+1 more
Genor Biopharma Co., Ltd. 72
Testing effectiveness (Phase 2)Study completedNCT00006760
What this trial is testing

Combination Chemotherapy in Treating Children With Refractory or Relapsed Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Children's Oncology Group 66
Early research (Phase 1)UnknownNCT03657381
What this trial is testing

Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520

Who this might be right for
Advanced Solid Tumor，Recurrent Solid Tumor，Lymphoma，Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma
Shandong New Time Pharmaceutical Co., LTD 75
Testing effectiveness (Phase 2)Study completedNCT00574496
What this trial is testing

Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center 25